Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16258601 | 0.85 | SIGMAR1 (0.39) | SIGMAR1CHRNB2CHRNA4CYP19A1CYP11B1 | |
| SCHEMBL28165447 | 0.78 | SIGMAR1 (0.35) | SIGMAR1CHRNB2CHRNA4 | |
| SCHEMBL15479677 | 0.77 | SIGMAR1 (0.32) | SIGMAR1CHRNB2CHRNA4 | |
| SCHEMBL16892310 | 0.77 | SIGMAR1 (0.32) | SIGMAR1CHRNB2CHRNA4 | |
| SCHEMBL14725544 | 0.75 | CYP11B2 (0.38) | SIGMAR1CHRNB2CHRNA4CYP19A1CYP11B1 | |
| SCHEMBL20661768 | 0.74 | SIGMAR1 (0.32) | SIGMAR1CHRNB2CHRNA4 | |
| SCHEMBL30317868 | 0.72 | CYP19A1 (0.37) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL8161816 | 0.72 | CYP19A1 (0.37) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL30825565 | 0.70 | SIGMAR1 (0.35) | SIGMAR1CHRNB2CHRNA4CYP19A1CYP11B1 | |
| SCHEMBL15093767 | 0.68 | ACHE (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10233156-B2 | 9-membered fused ring derivative | SHIONOGI & CO., LTD. (JP) | 2019-03-19 | — | — | US | disclosed |
| US-20180079727-A1 | 9-MEMBERED FUSED RING DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2018-03-22 | — | — | US | disclosed |
| US-20180079727-A1 | 9-MEMBERED FUSED RING DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079727-A1 | 9-MEMBERED FUSED RING DERIVATIVE | ACSS2, AGTR2, ACSL3 | SIGMAR1 1893/4885CHRNB2 914/4885CHRNA4 2242/4885 |
| US-10233156-B2 | 9-membered fused ring derivative | AGTR2, ACSS2, ACSL3 | SIGMAR1 1800/4885CHRNB2 950/4885CHRNA4 2161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.